Literature DB >> 12700700

Withdrawal from chronic phencyclidine treatment induces long-lasting depression in brain reward function.

Cecile Spielewoy1, Athina Markou.   

Abstract

Phencyclidine (PCP) is a drug of abuse that has rewarding and dysphoric effects in humans. The complex actions of PCP, and PCP withdrawal in particular, on brain reward function remain unclear. The purpose of the present study was to characterize the effects of withdrawal from acute and chronic PCP treatment on brain reward function in rats. A brain stimulation reward procedure was used to evaluate the effects of acute PCP injection (0, 5, or 10 mg/kg) or chronic PCP treatment (0, 10, 15, or 20 mg/kg/day for 14 days delivered via subcutaneous osmotic minipumps) on brain reward function. Withdrawal from acute administration of 5 and 10 mg/kg PCP produced a decrease in brain reward function as indicated by a sustained elevation in brain reward thresholds. When administered chronically, 10, 15, or 20 mg/kg/day PCP induced a progressive dose-dependent potentiation of brain stimulation reward, while cessation of the treatment resulted in significant elevations in reward thresholds reflecting diminished reward. Specifically, withdrawal from 15 or 20 mg/kg/day PCP induced a depression in brain reward function that lasted for the entire month of observation. These results indicate that prolonged continuous administration of high PCP doses facilitates brain stimulation reward, while withdrawal from acute high PCP doses or chronic PCP treatment results in a protracted depression of brain reward function that may be analogous to the dysphoric and anhedonic symptoms observed in PCP dependence, depression, and schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12700700     DOI: 10.1038/sj.npp.1300124

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  16 in total

1.  Effects of repeated withdrawal episodes, nicotine dose, and duration of nicotine exposure on the severity and duration of nicotine withdrawal in rats.

Authors:  Karen L Skjei; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2003-04-24       Impact factor: 4.530

Review 2.  Depression research: where are we now?

Authors:  Saebom Lee; Jaehoon Jeong; Yongdo Kwak; Sang Ki Park
Journal:  Mol Brain       Date:  2010-03-10       Impact factor: 4.041

3.  Personality measures in former heroin users receiving methadone or in protracted abstinence from opiates.

Authors:  L J Cohen; E Gertmenian-King; L Kunik; C Weaver; E D London; I Galynker
Journal:  Acta Psychiatr Scand       Date:  2005-08       Impact factor: 6.392

4.  Comparison of antidepressant-like and abuse-related effects of phencyclidine in rats.

Authors:  Todd M Hillhouse; Joseph H Porter; S Stevens Negus
Journal:  Drug Dev Res       Date:  2014-10-15       Impact factor: 4.360

5.  Repeated administration of aripiprazole produces a sensitization effect in the suppression of avoidance responding and phencyclidine-induced hyperlocomotion and increases D2 receptor-mediated behavioral function.

Authors:  Jun Gao; Rongyin Qin; Ming Li
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

6.  Analysis of licking microstructure provides no evidence for a reduction in reward value following acute or sub-chronic phencyclidine administration.

Authors:  Emma S Lydall; Gary Gilmour; Dominic M Dwyer
Journal:  Psychopharmacology (Berl)       Date:  2010-02-10       Impact factor: 4.530

7.  PCP-based mice models of schizophrenia: differential behavioral, neurochemical and cellular effects of acute and subchronic treatments.

Authors:  Anna Castañé; Noemí Santana; Francesc Artigas
Journal:  Psychopharmacology (Berl)       Date:  2015-05-07       Impact factor: 4.530

8.  Progressive ratio performance following challenge with antipsychotics, amphetamine, or NMDA antagonists in adult rats treated perinatally with phencyclidine.

Authors:  Jenny L Wiley; Amelia D Compton
Journal:  Psychopharmacology (Berl)       Date:  2004-07-08       Impact factor: 4.530

9.  Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats.

Authors:  Alice Egerton; Lee Reid; Sandie McGregor; Susan M Cochran; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2008-04-23       Impact factor: 4.530

10.  Behavioral processes mediating phencyclidine-induced decreases in voluntary sucrose consumption.

Authors:  John-Paul Baird; Sarah Turgeon; Aaron Wallman; Virginia Hulick
Journal:  Pharmacol Biochem Behav       Date:  2007-08-31       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.